Dr. Sam Sater, MD

Dr. Sater practices at Havasu Regional Medical Center in Lake Havasu City, Arizona, part of Lifepoint Health.

Dr. Sater's NPI, 1619256377, was assigned on August 12, 2011. Dr. Sater graduated from Lebanese University School of Medicine in 2007. Dr. Sater holds Florida license ME149649.

Dr. Sater's primary practice is Havasu Regional Medical Center, at 101 Civic Center Lane, Lake Havasu City, AZ 86403 in Mohave County. The practice phone is (928) 855-8185.

Dr. Sater's primary practice is Havasu Regional Medical Center in Lake Havasu City, Arizona, part of Lifepoint Health. Dr. Sater is also affiliated with Corewell Health Grand Rapids Hospitals - Butterworth. The medical group on file is Cancer Care of Western Arizona. Dmand AI also links Dr. Sater to 4 more hospitals, 6 medical groups, 4 group practices and clinics and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sater practices, 11 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Sater's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Sater is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Sater's licenses on file in 12 states: Florida, Michigan, Illinois, Pennsylvania, Tennessee, Alabama, Colorado, Indiana, Wisconsin, West Virginia, Maryland and Georgia.

Dmand AI lists breast cancer, chronic anemia, deep vein thrombosis (DVT), immune deficiency disease, lung cancer, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Sater treats.

CMS data shows 356 Medicare services from Dr. Sater across 6 procedure codes in 2024, for 268 Medicare patients. Medicare paid $24,439 for them.

CMS counts 268 Medicare patients who saw Dr. Sater in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sater's median patient age at 72, with 52% women.

In 2024, Dr. Sater wrote 164 Medicare Part D claims for 76 patients. 80% of them were for generic drugs. CMS names the drug for 58 of them, across 3 drugs with 11 or more claims each, at $843 in total drug cost. In 2023, CMS named 242 claims across 10 drugs.

Dr. Sater accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sater as offering telehealth.

Dmand AI links 2 papers to Dr. Sater in 2025. 2025 was the busiest year, with 2. The most frequent topics are Immune Checkpoint Inhibitors. Dr. Sater's most frequent co-authors are Margaret Elena Gatti-Mays, MD, James L. Gulley, MD, PhD, FACP and Fatima Hafiz Karzai, MD.

Dmand AI links Dr. Sater to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Penile Neoplasms.

CMS Open Payments shows 33 general payments to Dr. Sater from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 59% of the total. Daiichi Sankyo Inc. paid the most, $5,229.

Dr. Sater serves on Protocol Review Committee Cleveland Clinic.

Dr. Sater graduated from Lebanese University School of Medicine in 2007. Dr. Sater is a member of ASCO and Society for Immunotherapy of Cancer (SITC).

Dr. Sater is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.